Growing evidence, mainly consisting of single cases or small cohorts, suggests that daratumumab may offer clinical benefit in PRCA cases that are refractory to conventional therapies, given its mechanism of targeting and depleting CD38-positive cells that may contribute to the pathogenesis of PRCA [7–12]. This evidence concerns the gene CD38 and pure red-cell aplasia.